company valuation13 Jan 2020 18:06
We are now back to where we were valued in September 2017, so 2.5 years ago, the main culprits being the terrible CKHH secondary offering and the Savolitinib PRCC issue. Hopefully we are now well past any overhang from the CKHH placing and on pour way back towards a valuation we deserve.
Throughout that time I have continued to Buy, as I have done today.